Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
TROPION-Breast04 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab as neoadjuvant treatment for…